Literature DB >> 11939540

Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis.

N Miekeley1, S R Mortari, A O Schubach.   

Abstract

Results from a study are reported in which patients with leishmaniasis were monitored by whole blood, blood plasma, urine, and hair analysis, before, during, and after intramuscular administration of N-methyl meglumine antimoniate. Quadrupole ICP-MS was used for the detection of antimony and on-line ion chromatography for the separation of its species. After typically 30 consecutive daily injections of 5 mg antimony per kg of body weight, Sb concentrations of up to 250 microg L(-1) in whole blood and plasma, and 60 mg of Sb per gram of creatinine in urine, were measured 24 h after drug administration. Antimony in hair samples of these patients showed concentrations of up to 24 microg g(-1). Speciation studies of Sb5+ and Sb3+ in drug, urine, and plasma samples were performed by ion chromatography using a Hamilton PRP-100X anion exchange column and EDTA (2 or 20 mM, pH 4.7) as the mobile phases. Repeatability of elution time and peak area measurements for a 0.125 ng spike were <1.2% and <3.5%, respectively. Method detection limits for both species, using a 1:10 diluted urine or plasma sample, were typically 1.6 microg L(-1). The procedure was capable of separating the very intense drug peak from its inorganic species, thus permitting the first studies on the bio-transformation of N-methyl meglumine antimoniate to Sb5+ and Sb3+ in the human body.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11939540     DOI: 10.1007/s00216-001-1213-7

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  12 in total

1.  Parallel responses of human epidermal keratinocytes to inorganic SbIII and AsIII.

Authors:  Marjorie A Phillips; Angela Cánovas; Pei-Wen Wu; Alma Islas-Trejo; Juan F Medrano; Robert H Rice
Journal:  Environ Chem       Date:  2016-04-26       Impact factor: 3.088

2.  Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients.

Authors:  Débora Cristina de Oliveira Bezerra; Renata Oliveira de Barcelos; Ellen Carvalho de Castro; Claudia Cristina Jardim Duarte; Raquel de Vasconcellos Carvalhaes Oliveira; Tania Salgado de Sousa Torraca; Maria Helena de Araújo-Melo; Frederico Pereira Bom Braga; Benivaldo Ramos Ferreira Terceiro; Lúcia Regina do Nascimento Brahim Paes; Armando de Oliveira Schubach; Cláudia Maria Valete-Rosalino
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

3.  Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite.

Authors:  Marcela Luísa Gomes; Gilson DeFreitas-Silva; Priscila Gomes dos Reis; Maria Norma Melo; Frédéric Frézard; Cynthia Demicheli; Ynara Marina Idemori
Journal:  J Biol Inorg Chem       Date:  2015-05-01       Impact factor: 3.358

4.  Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.

Authors:  Vanessa Ribeiro Moreira; Luís Cláudio Lima de Jesus; Rossy-Eric Pereira Soares; Luis Douglas Miranda Silva; Bruno Araújo Serra Pinto; Maria Norma Melo; Antonio Marcus de Andrade Paes; Silma Regina Ferreira Pereira
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

5.  Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous Leishmaniasis in rhesus macaques (Macaca mulatta).

Authors:  G Grimaldi; R Porrozzi; K Friedrich; A Teva; R S Marchevsky; F Vieira; N Miekeley; F J R Paumgartten
Journal:  Antimicrob Agents Chemother       Date:  2009-10-12       Impact factor: 5.191

6.  First report on ototoxicity of meglumine antimoniate.

Authors:  Cláudia Maria Valete-Rosalino; Maria Helena Araujo-Melo; Débora Cristina de Oliveira Bezerra; Renata Oliveira de Barcelos; Vanessa de Melo-Ferreira; Tânia Salgado de Sousa Torraca; Ana Cristina da Costa Martins; João Soares Moreira; Mirian Catherine Melgares Vargas; Frederico Pereira Bom Braga; Mariza de Matos Salgueiro; Maurício Naoto Saheki; Armando Oliveira Schubach
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Sep-Oct       Impact factor: 1.846

Review 7.  Application of hyphenated techniques in speciation analysis of arsenic, antimony, and thallium.

Authors:  Rajmund Michalski; Sebastian Szopa; Magdalena Jabłońska; Aleksandra Łyko
Journal:  ScientificWorldJournal       Date:  2012-05-02

Review 8.  Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Authors:  Anke E Kip; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

9.  Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate.

Authors:  Deise Riba Coelho; Elaine Silva Miranda; Tatiana Dillenburg Saint'Pierre; Francisco José Roma Paumgartten
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-07       Impact factor: 2.743

10.  Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.

Authors:  Madelon Novato Ribeiro; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhães de Oliveira; José Liporage Teixeira; Madson Pedro da Silva Leite; Monique Fonseca; Ginelza Peres Lima dos Santos; Mariza Matos Salgueiro; Erica de Camargo Ferreira e Vasconcellos; Marcelo Rosandiski Lyra; Mauricio Naoto Saheki; Claudia Maria Valete-Rosalino
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jul-Aug       Impact factor: 1.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.